CULLINAN THERAPEUTICS

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2023 16:41:55 By Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

24 Jan 2023 08:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2023 17:13:42 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

14 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

02 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2022 17:23:46 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

01 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

25 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2022 16:50:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

07 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2022 17:27:22 By Nasdaq GlobeNewswire

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

15 Aug 2022 16:57:42 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

10 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2022 16:55:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in William Blair Biotech Focus Conference

05 Jul 2022 16:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2022 16:38:19 By Nasdaq GlobeNewswire

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

23 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jun 2022 17:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

31 May 2022 08:00:01 By Nasdaq GlobeNewswire